

Study: **ENGOT-ov77/ DS6000-109**

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers.

MaNGO Sites list

Prov	City	Site	Principal Investigator	Active
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	Yes
MB	Monza	Ospedale San Gerardo	Andrea A. Lissoni	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	Yes
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	Yes

* **MaNGO Principal Investigator**